Study identifier:H8O-CR-GWBH
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Safety and Efficacy of Exenatide Taken Before Lunch and Before Dinner Compared With Before Breakfast and Before Dinner in Patients With Type 2 Diabetes Using Oral Antidiabetic Therapy
Type 2 Diabetes
Phase 3
No
exenatide
All
377
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Eli Lilly and Company
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 - exenatide before breakfast and dinner | Drug: exenatide subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner) Other Name: Byetta |
Active Comparator: 2 - exenatide before lunch and dinner | Drug: exenatide subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner) Other Name: Byetta |